Literature DB >> 10981062

Antihypertensive drugs and diabetic nephropathy.

P S Mehler1, R W Schrier.   

Abstract

Diabetic nephropathy is the most common cause of end-stage renal disease in the United States. Hypertension is a major risk factor that predisposes individuals with diabetes to the development of renal disease and is very common in patients with diabetes. The benefit of blood pressure control on the rate of progression of diabetic nephropathy is being increasingly demonstrated in both type 1 and type 2 diabetic patients. Angiotensin converting enzyme inhibitors have proven renoprotective benefits in human studies, but the results of studies with calcium channel blockers are somewhat inconclusive. The other classes of antihypertensives also may have certain indications in the population of patients with diabetic nephropathy. In this paper we will critically review current strategies for the treatment of hypertension in patients with established diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10981062     DOI: 10.1007/s11906-999-0015-8

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  92 in total

1.  Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis.

Authors:  P Weidmann; M Schneider; L Böhlen
Journal:  Nephrol Dial Transplant       Date:  1995-10       Impact factor: 5.992

2.  Intermittent clinical proteinuria and renal function in diabetes: evolution and the effect of glycaemic control.

Authors:  J J Bending; G C Viberti; P J Watkins; H Keen
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-11

Review 3.  Renoprotection and renin-angiotensin system blockade in diabetes mellitus.

Authors:  L M Ruilope
Journal:  Am J Hypertens       Date:  1997-12       Impact factor: 2.689

4.  Systolic blood pressure relates to the rate of decline of glomerular filtration rate in type II diabetes.

Authors:  S Nielsen; A Schmitz; M Rehling; C E Mogensen
Journal:  Diabetes Care       Date:  1993-11       Impact factor: 19.112

5.  Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease.

Authors:  P McBride; H G Schrott; M B Plane; G Underbakke; R L Brown
Journal:  Arch Intern Med       Date:  1998-06-08

6.  Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus.

Authors:  H Yoshida; S Kuriyama; Y Atsumi; H Tomonari; T Mitarai; A Hamaguchi; H Kubo; Y Kawaguchi; V Kon; K Matsuoka; I Ichikawa; O Sakai
Journal:  Kidney Int       Date:  1996-08       Impact factor: 10.612

Review 7.  Hypertension-related renal injury: a major contributor to end-stage renal disease.

Authors:  W G Walker
Journal:  Am J Kidney Dis       Date:  1993-07       Impact factor: 8.860

8.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

9.  Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11

10.  Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis.

Authors:  Y Lacourcière; A Nadeau; L Poirier; G Tancrède
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.